End-Stage renal disease and 30-day mortality for adults with and without COVID-19

Stephanie L Harrison, Benjamin J R Buckley, Elnara Fazio-Eynullayeva, Paula Underhill, Deirdre A Lane, Gregory Y H Lip

Research output: Contribution to journalLetterpeer-review

2 Citations (Scopus)

Abstract

Emerging evidence suggests that people with chronic kidney disease have a higher risk of severe infection with coronavirus disease 2019 (COVID-19) [1]. Furthermore, acute kidney injury is common amongst patients hospitalised with COVID-19 compared to historical controls (56.9% vs. 25.1%) [2]. An estimated 726,000 people in the United States (US) are affected by end-stage renal disease (ESRD), and one-year mortality for people with ESRD who receive dialysis is approximately 20–25% [3]. Reports from China, England, Italy and France have suggested between 9% and 27% of patients with ESRD who tested positive for COVID-19 died, compared to 4% globally as of July 2020 [4]. The extent to which COVID-19 may worsen outcomes for people with ESRD is unclear. Therefore, the objective of this study was to compare 30-day mortality for people with ESRD and COVID-19 (cases) to matched people with ESRD before the COVID-19 pandemic (historical controls).
Original languageEnglish
Pages (from-to)93-95
Number of pages3
JournalEuropean Journal of Internal Medicine
Volume83
Early online date8 Nov 2020
DOIs
Publication statusPublished - Jan 2021
Externally publishedYes

Keywords

  • Renal disease
  • Mortality
  • COVID-19
  • Comorbidity
  • Chronic kidney disease

Fingerprint

Dive into the research topics of 'End-Stage renal disease and 30-day mortality for adults with and without COVID-19'. Together they form a unique fingerprint.

Cite this